Immune cell marker

Immune cell markers are a broad classification of proteins, primarily cell surface antigens, used to identify and distinguish various types of leukocytes and their functional states (NIH, 2023). These markers are most commonly organized under the Cluster of Differentiation (CD) system, which currently includes over 300 unique molecules such as CD3 for T cells, CD19 for B cells, and CD14 for monocytes (Zola et al., 2007). While the term itself describes a functional category rather than a single molecule, many specific markers within this group are critical therapeutic targets in oncology and immunology. For instance, CD20 is targeted by rituximab for B-cell lymphomas, and PD-1 is targeted by pembrolizumab for various solid tumors (Janeway's Immunobiology, 2017). These markers play diverse roles in cell signaling, adhesion, and the modulation of immune responses (Nature Reviews Immunology, 2021). In clinical practice, they are essential for immunophenotyping via flow cytometry to diagnose hematological malignancies and monitor immune-mediated diseases (StatPearls, 2023). Because 'Immune cell marker' is a collective noun for a vast array of proteins with distinct biological roles, it is not considered a single therapeutic target. Drug development must focus on specific, well-defined markers within this class to ensure efficacy and safety. Consequently, the term is too broad for specific drug-target interaction modeling without further specification of the individual protein.

Other names

Cluster of differentiation markersCD markersLeukocyte markersCell surface markersImmunophenotypic markers

Not applicable as this is a broad category of proteins rather than a single therapeutic target.